

Amendments to the Specification:

Please amend the specification as follows:

Please delete paragraph [0032] on page 7, and replace it with the following paragraph:

[0001] Figure 1: Shows the complete amino acid sequence and nucleic acid sequence of the AD7c-NTP gene and the AD7c-NTP protein product of that gene (Sequences 120 and 121 from U.S. Patent Nos. 5,830,670, 5,948,634, and 5,948,888; de la Monte *et al.*, *J. Clin. Invest.*, 100:3093-3104 (1997); NCBI Entrez-Protein Accession # AAC08737; PID g3002527) [**The nucleotide sequence is shown in SEQ ID NO: 1 and the encoded amino acid sequence is shown in SEQ ID NO: 10**].

Please delete paragraph [0061] on page 19, and replace it with the following paragraph:

[0002] The term “reverse-D peptide” refers to a biologically active protein or peptide consisting of D-amino acids arranged in a reverse order as compared to the L-amino acid sequence of an NTP protein, fragment, variant or homolog. Thus, the carboxy terminal residue of an L-amino acid NTP protein, fragment, variant or homolog becomes the amino terminal for the D-amino acid peptide and so forth. For example, the AD7c-NTP fragment, HVGQAG (**residues 62-67 of SEQ ID NO: 10**), becomes G_dA_dQ_dG_dV_dH_d, where A_d, G_d, H_d, Q_d, and V_d are the D-amino acids corresponding to the L-amino acids, A, G, H, Q, and V respectively.